Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 3, 2012, Pages

  Maric Bilkan, Christine ^a,b   Flynn, Elizabeth R ^a   Chade, Alejandro R ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Diabetes; Imaging; Vascular endothelial growth factor

Indexed keywords

4 AMINOHIPPURIC ACID; GROWTH FACTOR; INSULIN GLARGINE; IOTALAMIC ACID I 125; JG 12 PROTEIN; STREPTOZOCIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; IMMUNOREACTIVITY; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY VASCULAR RESISTANCE; MALE; MICRO-COMPUTED TOMOGRAPHY; MICROVASCULARIZATION; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENOVASCULAR DISEASE; STREPTOZOCIN DIABETES; THREE DIMENSIONAL IMAGING; WESTERN BLOTTING;

EID: 84856171497     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00421.2011     Document Type: Article

References (30)

1. Affonso FS, Cailleaux S, Pinto LF, Gomes MB, Tibirica E. Effects of high glucose concentrations on the endothelial function of the renal microcirculation of rabbits. Arq Bras Cardiol 81: 161-165, 156-160, 2003.
2. Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the US continues to decline. Diabetes Care 33: 73-77, 2010.
3. Gomes MB, Affonso FS, Cailleaux S, Almeida AL, Pinto LF, Tibirica E. Glucose levels observed in daily clinical practice induce endothelial dysfunction in the rabbit macro- and microcirculation. Fundam Clin Pharmacol 18: 339-346, 2004.
4. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72: 375-380, 1982.
5. Ichinose K, Maeshima Y, Yamamoto Y, Kinomura M, Hirokoshi K, Kitayama H, Takazawa Y, Sugiyama H, Yamasaki Y, Agata N, Makino H. 2-(8-Hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes 55: 1232-1242, 2006.
6. Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K, Makino H. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 54: 2891-2903, 2005.
7. Iliescu R, Chade AR. Progressive renal vascular proliferation and injury in obese Zucker rats. Microcirculation 17: 250-258, 2010.
8. Iliescu R, Fernandez SR, Kelsen S, Maric C, Chade AR. Role of renal microcirculation in experimental renovascular disease. Nephrol Dial Transplant 25: 1079-1087, 2010.
9. Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia 53: 2093-2104, 2010.
10. Josifova T, Schneider U, Henrich PB, Schrader W. Eye disorders in diabetes: potential drug targets. Infect Disord Drug Targets 8: 70-75, 2008.
11. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM. VEGFdependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290: H560-H576, 2006.
12. Karalliedde J, Gnudi L. Future strategies to prevent renal microvascular disease complications in diabetes. Future Cardiol 4: 77-83, 2008.
13. Khavandi K, Greenstein AS, Sonoyama K, Withers S, Price A, Malik RA, Heagerty AM. Myogenic tone and small artery remodelling: insight into diabetic nephropathy. Nephrol Dial Transplant 24: 361-369, 2009.
14. Krentz AJ, Clough G, Byrne CD. Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. Diabetes Obes Metab 9: 781-791, 2007.
15. Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A, Eichinger F, Gaiser S, Schmid H, Rastaldi MP, Schrier RW, Schlondorff D, Cohen CD. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol 18: 1765-1776, 2007.
16. Mankhey R, Wells CC, Bhatti F, Maric C. 17-β Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 292: R769-R777, 2007.
17. Marre M, Hallab M, Roy J, Lejeune JJ, Jallet P, Fressinaud P. Glomerular hyperfiltration in type I, type II, and secondary diabetes. J Diabetes Complications 6: 19-24, 1992.
18. Nakagawa T. A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism. Clin Nephrol 71: 103-109, 2009.
19. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 292: F1665-F1672, 2007.
20. Nakagawa T. Uncoupling of VEGF with NO as a mechanism for diabetic nephropathy. Diabetes Res Clin Pract 82, Suppl 1: S67-S69, 2008.
21. Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA. Abnormal angiogenesis in diabetic nephropathy. Diabetes 58: 1471-1478, 2009.
22. Nawroth PP, Isermann B. Mechanisms of diabetic nephropathy- old buddies and newcomers part 1. Exp Clin Endocrinol Diabetes 118: 571-576, 2010.
23. Nawroth PP, Isermann B. Mechanisms of diabetic nephropathy- old buddies and newcomers part 2. Exp Clin Endocrinol Diabetes 118: 667-672, 2010.
24. Osterby R, Nyberg G. New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy. J Diabetes Complications 1: 122-127, 1987.
25. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 109, Suppl 2: S424-S437, 2001.
26. Roberts DM, Kearney JB, Johnson JH, Rosenberg MP, Kumar R, Bautch VL. The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol 164: 1531-1535, 2004.
27. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis 218: 13-18, 2011.
28. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65: 2003-2017, 2004.
29. Xu Q, Wells CC, Garman JH, Asico L, Escano CS, Maric C. Imbalance in sex hormone levels exacerbates diabetic renal disease. Hypertension 51: 1218-1224, 2008.
30. Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, Sugiyama H, Yamasaki Y, Makino H. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 53: 1831-1840, 2004.